Jeff Jones, Cullinan Oncology CMO
#ASCO22: With median durability data, Cullinan aims to 'distinguish itself' from Takeda's Exkivity and J&J's Rybrevant in exon 20 NSCLC
CHICAGO — In its “first time on a bigger stage” at this weekend’s ASCO conference, Cullinan Oncology thinks it has the data to “distinguish itself” …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.